Incyte Corp (INCY) Stock Price, Quote & News

Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a select...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 498 6700

Website: www.incyte.com

Address:

1801 Augustine Cut-Off, Wilmington, United States

ZacksResearch Aug. 20 at 2:19 PM

$INCY recently hit a 52-week high — is it time to cash in? 🚀 Jakafi's 15% sales increase in the first half of 2025 and recent drug approvals are driving momentum, but the looming patent expiration poses a risk. The Zacks Consensus Estimate for 2025 EPS has also risen to $6.07, reflecting strong earnings potential. Stay informed with a full analysis here 👉 https://www.zacks.com/stock/news/2740282/incy-stock-trading-close-to-its-52-week-high-buy-sell-or-hold?cid=sm-stocktwits-2-2740282-body-8567&ADID=SYND_STOCKTWITS_TWEET_2_2740282_BODY_8567

0 · Reply

ZacksResearch Aug. 20 at 1:19 PM

$INCY at fresh 52-week highs — is the rally just getting started? 🚀 Jakafi + Opzelura sales strength, pipeline wins, and bullish sentiment are all fueling momentum. Full buy/sell/hold breakdown here 👉 https://www.zacks.com/stock/news/2740282/incy-stock-trading-close-to-its-52-week-high-buy-sell-or-hold?cid=sm-stocktwits-2-2740282-teaser-8566&ADID=SYND_STOCKTWITS_TWEET_2_2740282_TEASER_8566

0 · Reply

sck2 Aug. 18 at 2:37 PM

$SNDX I will take $45 ... lets go $INCY we're golden and you know it.

0 · Reply

Polip Aug. 18 at 2:34 PM

$SNDX BO 25 -30 usd per share very possible. $INCY

0 · Reply

Night_Owl_Biotech Aug. 15 at 1:19 PM

Hypothetical $SNDX M&A valuation using SWTX peer Year 4 M&A revenue multiples & SNDX FY2029 revenue estimates per Seeking Alpha. You'll see hypothetical M&A valuations using the lowest peer Year 4 multiple & lowest revenue estimate, the average & the highest. It is quite a range. This is just for fun. We have no idea if SWTX peers are appropriate for SNDX. However, SNDX reports gross margin % in the high 90s where SWTX projected low 80s. We also have no idea if SNDX revenue estimates are credible. Also, obviously since we are in August 2025, SNDX year 4 should be the last 4 months of 2027 & the first 8 months of 2028. Our point is this is not perfect but does suggest a compelling risk reward profile should $INCY acquire SNDX. For all we know SNDX could fail so this is not investment advice. We only suggest investors research SNDX for themselves. $XBI $NBI $LABU

1 · Reply

ilhami Aug. 14 at 7:56 PM

$INCY The giant "falling wedge" formation on the monthly chart (approximately 10 years old) is extremely regular. The breakout has occurred. A long-term uptrend is expected.

1 · Reply

Night_Owl_Biotech Aug. 14 at 5:35 PM

It is terrific $SNDX is up ~40% since its Q2 2025 conference call but investors should remember SNDX is still off 33% from last November. More important, SNDX still only trades for 0.16X its 10-year revenue forecast where peer 10-year M&A revenue multiples range from 0.33 to 0.42X. We should also reference our previous posts noting non-oncology multiples were considerably higher than oncology. This is not investment advice. We have no idea what will happen to SNDX but simple analytics suggest there's still considerable upside should $INCY acquire SNDX. We have no idea whether a M&A exit will happen. We also cannot be sure SNDX revenue forecasts are credible nor if SNDX's 2 products warrant a peer M&A multiple. For all we know valuations could crash & SNDX could go bankrupt. We only suggest you fully research SNDX for yourself. The attachment visually compares SNDX's 10-year revenue multiple at $14.30/share versus M&A revenue multiples paid in peer acquisitions. $XBI

3 · Reply

Nomorelies Aug. 13 at 2:32 PM

$INCY The gift that keeps on giving!

0 · Reply

StockAutoPro Aug. 12 at 3:47 PM

$INCY: Buy target $78.26 Sell target $84.27 Pharmaceutical company's successful cancer immunotherapy trials could lead to a breakthrough, expect potential stock growth.

0 · Reply

Nomorelies Aug. 12 at 1:44 PM

$INCY WOW!!!

0 · Reply

Incyte to Present at Upcoming Investor Conferences

Aug 15, 2025, 8:52 AM EDT - 8 days ago

20 stocks in the S&P 500 that are high achievers this earnings season

ANET APH COIN CTRA EQT EXE FICO

Aug 5, 2025, 4:05 PM EDT - 18 days ago

Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis

Aug 1, 2025, 8:31 AM EDT - 22 days ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Aug 1, 2025, 6:54 AM EDT - 22 days ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Jul 31, 2025, 4:30 PM EDT - 23 days ago

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

Jul 29, 2025, 1:33 PM EDT - 25 days ago

Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 11:13 AM EDT - 25 days ago

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand

Jul 29, 2025, 8:30 AM EDT - 25 days ago

Incyte lifts annual sales forecast for blood cancer drug after solid quarter

Jul 29, 2025, 7:00 AM EDT - 25 days ago

Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Jul 24, 2025, 5:02 PM EDT - 4 weeks ago

Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025

Jul 10, 2025, 8:00 AM EDT - 6 weeks ago

Incyte to Report Second Quarter Financial Results

Jul 3, 2025, 6:11 AM EDT - 7 weeks ago

Incyte: New CEO Brings A New Possible Outcome

Jul 2, 2025, 4:30 PM EDT - 7 weeks ago

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 26, 2025, 7:30 AM EDT - 2 months ago

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

Jun 20, 2025, 5:10 PM EDT - 2 months ago

Incyte Says FDA Extended Review Period for Opzelura

Jun 18, 2025, 4:12 PM EDT - 2 months ago

Incyte Lymphoma Treatment Gets FDA Approval

$Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma$

Jun 18, 2025, 3:39 PM EDT - 2 months ago

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Jun 15, 2025, 4:00 AM EDT - 2 months ago

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

QGEN

Jun 15, 2025, 3:15 AM EDT - 2 months ago

Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Jun 12, 2025, 6:45 PM EDT - 2 months ago

Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Jun 6, 2025, 4:30 PM EDT - 2 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 3, 2025, 10:30 AM EDT - 2 months ago

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

Jun 2, 2025, 12:15 PM EDT - 2 months ago

20 stocks primed for rapid growth while trading at half of Nvidia's valuation

AIG APTV BALL CTRA DELL DVA ELV

May 27, 2025, 8:00 AM EDT - 3 months ago

Incyte to Present at Upcoming Investor Conference

May 15, 2025, 2:30 PM EDT - 3 months ago

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

May 12, 2025, 11:18 AM EDT - 3 months ago

20 stocks of companies showing excellent earnings-season trends even as the economy cools

AMD APH CF CTRA DVN ENPH EQT

Apr 29, 2025, 12:53 PM EDT - 4 months ago

Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 9:03 AM EDT - 4 months ago

Incyte raises 2025 sales forecast for blood cancer drug after solid quarter

Apr 29, 2025, 7:00 AM EDT - 4 months ago

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Apr 25, 2025, 8:00 AM EDT - 4 months ago

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025

Apr 23, 2025, 11:03 AM EDT - 4 months ago

Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 10, 2025, 8:00 AM EDT - 4 months ago

Incyte to Report First Quarter Financial Results

Mar 31, 2025, 5:02 PM EDT - 5 months ago

These 20 worst-performing stocks in the S&P 500 sank 17% or more in March

DAL BBY CCL CEG CZR DECK DXCM

Mar 26, 2025, 7:30 AM EDT - 5 months ago

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

Mar 18, 2025, 3:39 PM EDT - 5 months ago

Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib

Mar 17, 2025, 12:30 PM EDT - 5 months ago

Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results

Mar 17, 2025, 11:21 AM EDT - 5 months ago

Incyte Is Today's Worst S&P 500 Stock. Here's Why.

Mar 17, 2025, 9:53 AM EDT - 5 months ago

Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls

Mar 17, 2025, 8:58 AM EDT - 5 months ago

Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

TSLA

Mar 17, 2025, 7:10 AM EDT - 5 months ago

Incyte's skin disease drug meets main goal in two late-stage studies

Mar 17, 2025, 7:00 AM EDT - 5 months ago

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

Mar 8, 2025, 1:00 PM EST - 6 months ago

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

LLY

Mar 8, 2025, 9:01 AM EST - 6 months ago

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting

Feb 28, 2025, 9:30 AM EST - 6 months ago

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

Feb 20, 2025, 8:00 AM EST - 6 months ago

Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration

Feb 12, 2025, 8:30 AM EST - 6 months ago

Reevaluating Incyte Corporation After Earnings (Technical Analysis)

Feb 11, 2025, 7:30 AM EST - 6 months ago

Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025

Feb 10, 2025, 11:52 AM EST - 6 months ago

Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript

Feb 10, 2025, 8:38 AM EST - 6 months ago

Incyte reports quarterly sales above estimates on strong demand for key drugs

ZacksResearch Aug. 20 at 2:19 PM

0 · Reply

ZacksResearch Aug. 20 at 1:19 PM

0 · Reply

sck2 Aug. 18 at 2:37 PM

$SNDX I will take $45 ... lets go $INCY we're golden and you know it.

0 · Reply

Polip Aug. 18 at 2:34 PM

$SNDX BO 25 -30 usd per share very possible. $INCY

0 · Reply

Night_Owl_Biotech Aug. 15 at 1:19 PM

1 · Reply

ilhami Aug. 14 at 7:56 PM

$INCY The giant "falling wedge" formation on the monthly chart (approximately 10 years old) is extremely regular. The breakout has occurred. A long-term uptrend is expected.

1 · Reply

Night_Owl_Biotech Aug. 14 at 5:35 PM

3 · Reply

Nomorelies Aug. 13 at 2:32 PM

$INCY The gift that keeps on giving!

0 · Reply

StockAutoPro Aug. 12 at 3:47 PM

$INCY: Buy target $78.26 Sell target $84.27 Pharmaceutical company's successful cancer immunotherapy trials could lead to a breakthrough, expect potential stock growth.

0 · Reply

Nomorelies Aug. 12 at 1:44 PM

$INCY WOW!!!

0 · Reply

Night_Owl_Biotech Aug. 11 at 6:19 PM

$SNDX projected revenues compared to $VIE & $CTIC when they were acquired (attached graph). SNDX is expected to generate more sales dollars than VIE when VIE was acquired for $2.7B & at a higher gross margin. SNDX's market cap = $1.1B at $12.50/share. VIE was acquired for 0.39X it cumulative 10 year revenue forecast while SNDX trades for less than 0.13X. Of course we c/b wrong but we strongly suspect $INCY will acquire SNDX by year end & strongly encourage investors to do their own research. Even CTIC, whose patent expired at the end of year 10 from its M&A date, was acquired for 0.33X its 10-year revenue forecast. SNDX could end up in bankruptcy for all we know. We just like its risk v reward profile at a $1.1B market cap when analysts expect Revuforj & Niktimvo (or 50% of Niktimvo) to be north of $1B/year. This is not investment advice. $XBI

1 · Reply

Doozio Aug. 7 at 7:49 PM

$INCY $WGS are biotechs that act like $LGND ary 🧠leader🐑 ready to continue TTWO $ASND during 🐒🍌🧠⏰♾️

0 · Reply

JarvisFlow Aug. 6 at 12:31 PM

Wells Fargo has adjusted their stance on Incyte ( $INCY ), setting the rating to Overweight with a target price of 67 → 89.

0 · Reply

Psalms23 Aug. 5 at 8:30 PM

$INCY both the CEO and CFO departed. Not a good sign

1 · Reply

Night_Owl_Biotech Aug. 5 at 2:26 PM

$SNDX is up this morning but, at $12.27/share, has a market cap of $1.051B per Yahoo Finance. SNDX's market cap is ~0.14X cumulative 10-year revenue estimates while peers are generally acquired for 0.33 to 0.42X their 10-year revenue estimates. SNDX revenue estimates do not consider Niktimvo US sales (recorded by $INCY) which means any Niktimvo US valuation does not manifest in SNDX's multiples. This is not investment advice because there may be a very good reason SNDX trades at such a large discount to its hypothetical M&A valuation using peer multiples. $VRNA published the financial projection provided $JNJ this morning. VRNA's 10-year revenue projections were roughly 20% higher than analyst consensus at the time the acquisition was announced. Hence VRNA's 10-year revenue multiple using their own estimates was 0.36X. Again, this is not investment advice as we've never been able to predict what will happen to the price of any stock. $XBI

3 · Reply

Quantumup Aug. 5 at 12:10 PM

BTIG⬆️the PT on $SNDX to $56 from $43 and reiterated at Buy. $KURA $INCY BTIG said in its note:

1 · Reply

Quantumup Aug. 5 at 11:52 AM

Clear Street reiterated $MLTX Buy/$108 after a recent fireside chat with Moonlake reinforced its conviction in SLK's potential as a blockbuster, w/ pivotal Vela trial data for Hidradenitis Suppurativa (HS) anticipated in September. $UCBJY $NVS $LLY $INCY Clear Street said in its note: "Leveraging the more robust HiSCR75 endpoint—historically less prone to placebo noise than HiSCR50—alongside consistent P2 Mira design, rigorous site training, and enriched P2 Mira site recruitment, Vela is well-positioned to surpass the 20% HiSCR75 benchmark. Coupled with a best-in-class safety and convenience profile, and FDA-mandated secondary endpoints that deliver unprecedented clinical relevance to both physicians (IHS4) and patients (NRS, DLQI), SLK is uniquely positioned to achieve market leadership through multiple avenues of differentiation."

0 · Reply

Quantumup Aug. 5 at 11:41 AM

Goldman Sachs⬆️ $SNDX PT to $20 from $18 and reiterated at a Buy rating. $KURA $INCY Goldman Sachs said in its note:

0 · Reply

2_logs_higher Aug. 4 at 10:58 PM

$AGEN $INCY Tell new ceo at INCY to buy Agenus with conviction. www.fiercepharma.com/pharma/incytes-new-ceo-pledges-fresh-look-business-outlines-dealmaking-strategy

2 · Reply

Nomorelies Aug. 4 at 4:16 PM

$INCY

0 · Reply

Night_Owl_Biotech Aug. 3 at 6:12 PM

Even a casual review of stock price graphs of commercial-stage oncology focused bios tells you last week was tough on this peer group that historically outperforms non-oncology (as multiples of projected revenues). This coming week is, arguably, the most exciting of the quarter when a majority of bios with FDA approved therapies report on their launches. This is why it is puzzling most oncology shares did so poorly as there appears no really bad news. In fact it appears $INCY did well. $DAWN hit $7.37 then fell down at a 45 degree angle before recovering Friday The attached table lists the 8/1/25 closing share prices and change in share price from the previous week's closing high for all 27 commercial-stage oncology focused bios with market caps north of $150MM (excl. RIGL). Half were off by more than 10% & 2/3 were off by more than 7%. $URGN what can you say :) This is not investment advice but we still like $SNDX as we believe INCY will acquire them by year end. $DCTH

3 · Reply

StocktwitsNews Aug. 1 at 6:58 PM

Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer $INCY $PKW https://stocktwits.com/news/equity/markets/barclays-initiates-incyte-with-overweight-rating-90-dollar-price-target/chrEeLARdRd

0 · Reply

Market Cap	16.90B
Revenue (ttm)	4.24B
Net Income (ttm)	32.61M
EPS (ttm)	N/A
PE Ratio	21.44
Forward PE	17.03
Profit Margin	0.77%
Debt to Equity Ratio	0.00

Volume	1,475,700
Avg Vol	1,790,616
Day's Range	N/A - N/A
Shares Out	195.28M
Stochastic %K	72%
Beta	0.71
Analysts	Sell
Price Target	$82.45